Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F List

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Bone Marrow Transplantation|February 16, 2000
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study GroupA F List, R Maziarz, P Stiff, et al.
Blood|March 15, 1996
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemiaA F List, C S Spier, T M Grogan, et al.
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Blood|November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group studyA F List, K J Kopecky, C L Willman, et al.
Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Leukemia|March 14, 2009
Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndromeJ X Zou, D E Rollison, D Boulware, et al.
Leukemia|October 18, 2012
Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiencyL Yang, A Mailloux, D E Rollison, et al.
Leukemia|August 26, 2016
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomideE Negoro, T Radivoyevitch, C Polprasert, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Bone Marrow Transplantation|February 16, 2000
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study GroupA F List, R Maziarz, P Stiff, et al.
Blood|March 15, 1996
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemiaA F List, C S Spier, T M Grogan, et al.
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Blood|November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group studyA F List, K J Kopecky, C L Willman, et al.
Leukemia|July 16, 2011
A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemiaJ E Lancet, F Ravandi, R M Ricklis, et al.
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Leukemia|March 14, 2009
Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndromeJ X Zou, D E Rollison, D Boulware, et al.
Leukemia|October 18, 2012
Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiencyL Yang, A Mailloux, D E Rollison, et al.
Leukemia|August 26, 2016
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomideE Negoro, T Radivoyevitch, C Polprasert, et al.
Pageof 10